Gagilapur FDA warning letter resolution timeline uncertain
Management could not provide a timeline for FDA reinspection or final resolution, which may delay new product launches from the site.
GRANULES / Q3-FY26 / risks
Keep the risk register visible.
Granules India · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Peptide CDMO quarterly volatility may persist
Despite expected Q4 improvement, management acknowledged quarter-to-quarter variation is inherent to the CDMO business, posing risk to sustained profitability.
Paracetamol price erosion despite volume recovery
While inventory levels have eased and volumes are building, management noted price erosion in paracetamol, which could pressure margins.
Tentative approval for amphetamine product may take a year for final approval
The generic Adderall approval is tentative due to IP issues; final approval may take a year, delaying potential revenue contribution.